Advancements in vaccine development for parasitic infections, particularly malaria, are crucial for reducing global health burdens in vulnerable populations.

Current mRNA-based vaccines for COVID-19 from Pfizer/BioNTech and Moderna have been ... at other candidates for indications like flu, malaria, tuberculosis, rabies and respiratory syncytial ...

Regarding infectious diseases, BioNtech is pursuing vaccines for shingles, Herpex, tuberculosis, malaria and Mpox. Among those, the diseases affecting the most people are Herpex viruses (3.7 billion ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.

German pharmaceutical company BioNTech was back in profit in the third quarter of 2024, it announced on Monday, with comparatively early approvals for adapted coronavirus vaccines driving up sales.

Vaccines that prevent smallpox and mpox come in two varieties. One uses a single shot of a live virus but carries the risk of ...